ClinicalTrials.gg
RecruitingNCT07529275fenCoUpdated Apr 14, 2026

Clinical Performance and Safety Assessment of the Use of iCover Balloon Expandable Covered Stent (iVascular) Implanted as Bridging Stent in FEVAR (Fenestrated Endovascular Aortic Repair) for the Treatment of Complex Abdominal Aortic Aneurysms

An interventional study of iCover balloon-expandable covered peripheral stent system as bridging stent in Complex Abdominal Aortic Aneurysms, sponsored by iVascular S.L.U.. Recruiting at 24 sites in 5 countries. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-04-14.

Sponsored by iVascular S.L.U. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
165
Allocation
Not applicable
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies in Aortic Aneurysm, Abdominal with a site in France — 10 open to participants now, 13 under way, none of them phase 3. Aortic Aneurysm, Abdominal · France.

Planned enrollment
12th of 26
165 · median 103
Started
2026
with 1 other
No phase
22 of 59
6 open now
Primary completion
2028-06
later than 10 of 12 live
Registered
58th of 59
by date
Lead sponsor
2 of 59
iVascular S.L.U.

Among the 59 studies in Aortic Aneurysm, Abdominal with a site in France, this one is the 12th largest by planned enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2026, is one of 22 with no phase, reaches primary completion later than 10 of the 12 other live ones, and was the 58th registered.

Aortic Aneurysm, Abdominal

467 studies on the registry are indexed under Aortic Aneurysm, Abdominal; 99 are open to participants now.

Browse Aortic Aneurysm, Abdominal studies →

Open to participants now

10 of the 59 studies in Aortic Aneurysm, Abdominal with a site in France are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 66 Aortic Aneurysm, Abdominal studies recruiting now, 52 (79%) set no upper age limit and 3 (5%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Aortic Aneurysm, Abdominal with a site in France, or all of them as a file.
02

Study summary

fenCo is a European multicentre, prospective study to evaluate the use of the iCover covered stents as bridging stents for reno-visceral target vessel during fEVAR for the treatment of complex abdominal aortic aneurysms.

Read the detailed description

In terms of complex endovascular repair, fenestrated stent grafts should be considered the preferred treatment option when feasible. The main advantage of Fenestrated Endovascular Aneurysm Repair (fEVAR) lies in the avoidance of aortic cross clamping and subsequent lower risk of renal dysfunction, less surgical trauma and faster recovery, which may be advantageous for patients at high risk for open surgery. fenCo study aims to demonstrate the safety and efficacy of iCover when used as bridging stent in fEVAR procedures for the treatment of complex abdominal aortic aneurysms.

03

Conditions studied

  • Complex Abdominal Aortic Aneurysms

Keywords

  • FEVAR
  • bridging stent
  • complex abdominal aortic aneurysms
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient suitable for treatment of a juxta, para-renal, suprarenal or thoracoabdominal aneurysm with a fenestrated endoprosthesis in accordance with current indications and guidelines for the management of abdominal aortic aneurysms (aneurysm > 5 centimetres for women and > 5.5 centimetres for men and/or growth > 5 mm in 6 months or 1 centimetre in 1 year).
  2. The fenestrated endograft must be designed in a way that positions the fenestrations directly in front of the orifice of the target vessel, ensuring that the distance between the fenestration and the orifice of the target vessel does not exceed 5 mm.
  3. Anatomy and patient strictly in accordance with the Instructions For Use (IFU) of the fenestrated endograft chosen to be implanted:

    1. Cook Medical: Zenith Fenestrated AAA Endovascular Graft
    2. Terumo Aortic: TREO and Anaconda Fenestrated Stent Grafts
    3. JOTEC (part of Artivion): E-xtra design engineering.
  4. Additional iCover stent, if necessary, could be placed in the same target artery (2 iCovers stents max as bridging stent for each fenestration).
  5. Landing zone in the target vessel of at least 10 mm.
  6. Target arteries (renal arteries, superior mesenteric artery, celiac trunk) with a diameter between 5 and 10 mm.
  7. Angulation of the aorta at the level of the target vessels \< 45 degrees.
  8. No early significant branching from the target vessel with a potential risk of coverage and subsequent significant risk of target organ infarctions.
  9. Age > 55 years.
  10. Patient having notified his consent to this study and willing to comply with specified follow-up evaluations at the specified times.
  11. Patient affiliated to or benefiting from a social security system.
  12. Patient with > 12 months.

Exclusion criteria

Exclusion Criteria:

  1. Patients for anti- therapy.
  2. Patients with uncontrolled haematological disorders or heparin-induced thrombocytopenia.
  3. Chronic or acute aortic dissection.
  4. Patients refusing treatment.
  5. Patients who are pregnant or wish to become pregnant.
  6. Patients scheduled for major or life-saving surgery within 30 days of the fenestrated stent procedure.
  7. Patients considered hemodynamically unstable or requiring emergency treatment.
  8. Patients with severe arteriopathy leading to adverse outflow, which may impair bridging stent patency on the targeted artery.
  9. Thrombus in the aortic sealing zone and target arteries with thickness > to 3 mm.
  10. Stenosis (>50%) or occlusion of target arteries or distal disease resulting in poor iCover stent outflow.
  11. Patients allergic to stent materials (L605) and/or PTFE.
  12. Patients requiring a hybrid aortic technique with branches, semibranches or chimneys.
  13. Patient who has been implanted with any stent type or brand other than iCover as a bridging stent in any target artery.
  14. Patients with infectious/mycotic aneurysms.
  15. Angulation between renal artery and aortic wall \< 30 degrees.
  16. Patients with complex iliac accesses out the IFUs of the fenestrated endograft chosen to be implanted (COOK Medical / Terumo Aortic/Jotec-Artivion) with the iCover Bridging stent.
  17. Patient is currently participating in another drug or device study that has not completed the entire follow up period that may interfere with the results of this study.
  18. Myocardial infarction or stroke within 3 months prior to the procedure.
  19. Patients with an unstable angina pectoris or heart insufficiency 3 or 4.
  20. Patients with 5 or higher.
  21. Patients with physician modified endografts or in situ laser FEVAR.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
165 participants (estimated)

Study arms

  • Experimental
    iCover balloon-expandable covered peripheral stent system

    iCover balloon-expandable covered peripheral stent system

    Device: iCover balloon-expandable covered peripheral stent system as bridging stent

Interventions

  • DeviceiCover balloon-expandable covered peripheral stent system as bridging stent

    This device will be used as bridging stent during FEVAR (fenestrated endovascular aortic repair) procedures.

06

What researchers measure

Primary outcomes

  1. Bridging stent patency at 12-month visit

    Defined as rate of stents with an absence of binary restenosis (≥ 50% stenosis) based on CT Angio at 12 months visit (+/-2 months).

    Time frame: 12 months visit

  2. Absence of target vessel instability between implantation and 12-month visit.

    Defined as rate of patients with an absence of target vessel instability described as a composite endpoint of any branch-related complication leading to: aneurysm rupture/ death/ occlusion/ component separation/ or reintervention to maintain branch patency or to treat a branch-related component separation or endoleak between implantation and 12 months visit (+/-2 months).

    Time frame: starting at implant day through the study completion, with an average of 12Months up to 14Months per window.

Secondary outcomes

  1. Technical success: Successful introduction and deployment of the iCover stent implanted as bridging stent in FEVAR procedure.

    Defined as rate of stents with successful introduction and deployment of the iCover (iVascular) implanted as bridging stent in FEVAR.

    Time frame: During the index procedure (from stent introduction to final deployment, up to procedure completion)

  2. Bridging stent patency at the first postoperative imaging, at 6 and at 12 months visits.

    Defined as rate of stents without binary restenosis \> 50% or occlusion on duplex scan and/or angioCT scan examination, or angiography at discharge at 6 and 12 months visits.

    Time frame: at discharge visit (up to 3 months, average of 7days) and at 6 and 12 months visits ( can be up to 8 and 14months from implant day)

  3. Absence of endoleaks linked to iCover covered stent defects at the first postoperative imaging, at 6 and 12 months visits.

    Defined as rate of stents without endoleaks linked to iCover covered stent defects (Malposition, rupture or disconnection) on Duplex scan, angio CTscan or angiography at discharge visit, at 6 months visits and at 12 months visit.

    Time frame: discharge visit , 6 and 12 months visits.

  4. Absence of re-intervention due to a technical defect in iCover covered stents at discharge, at 6 months visit, and at 12 months visit.

    Defined as rate of stents without re-intervention due to a technical defect in iCover covered stents post-procedure between surgery and post operative to discharge period, between surgery and 6 months visit, between surgery and 12 months visit.

    Time frame: between surgery and post operative to discharge period, between surgery and 6 months visit, between surgery and 12 months visit.

  5. Absence of type I or III endoleaks post-procedure at the first postoperative imaging, at 6 and 12 months visits.

    Defined as rate of stents without type I or III endoleaks post-procedure on duplex scan, angio CTscan or angiography at discharge period, 6 months visit and at 12 months visit.

    Time frame: discharge visit, 6 and 12 months visits.

  6. 30-day post-procedure mortality.

    Defined as rate of post-procedure mortality (all causes) within 30-day post procedure.

    Time frame: within 30 days post procedure

  7. In-hospital post-procedure mortality (all causes).

    Defined as rate of In-hospital post-procedure mortality (all causes).

    Time frame: between procedure and 12 months visit

  8. Absence of aortic endograft migration at 6 months visit and at 12 months visit.

    Defined as rate of endografts without aortic migration \> 10 mm at 6 Months visit and 12 months visit.

    Time frame: at 6 and 12 months visits

  9. No increase in maximum aneurysmal sac diameter measured by CT angiography at 6 and at 12 months visits.

    Defined as rate of patients without increase of \> 5 mm in maximum aneurysmal sac diameter compared with post-procedure angio CT scan measured by angio CT scan at 6 and 12 months visits.

    Time frame: at 6 and 12 months visits

  10. Absence of post-procedural aortic surgical conversion at discharge, at 6 and 12 months visits.

    Defined as absence of post-procedural aortic surgical conversion between the implantation and the follow-up visits

    Time frame: between implant and 6 and 12 months visits

  11. Absence of aneurysm-related mortality post-procedure at discharge, at 6 months and 12 months visits.

    Defined as absence of aneurysm-related mortality post-procedure between the implantation and the follow-up visits.

    Time frame: between implant and 6 and 12 months visits

  12. Absence of aneurysm related secondary endovascular procedures at discharge, at 6 and 12 months visits.

    Defined as absence of aneurysm related secondary endovascular procedures between the implantation and the follow-up visits.

    Time frame: between implant 6 and 12 months visits.

  13. Absence of major adverse events (MAEs) at discharge, at 6 and 12 months visits.

    Defined as aortic rupture, aneurysm-related death, in-hospital death, decline in renal function (by at least 20%), lower extremity ischemia, mesenteric ischemia, or unplanned reintervention between the implantation and the follow-up visits.

    Time frame: between implant and 6, 12 months vists.

  14. Absence of target vessel instability at 12 months visit.

    Absence of target vessel instability at 12 months visit.

    Time frame: at 12 months visit

  15. Target vessel patency at at 6 and 12 months visits

    Defined as proportion of target vessel patency at 6 and 12 months.

    Time frame: 6 and 12 months visits

07

Study locations

1 of 24 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jun 2028, 28 months after the start.

Of 43 industry-sponsored interventional studies with no phase under Aortic Aneurysm, Abdominal, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 73. This study's planned 28 months is below that.

Counting every sponsor, half of 94 studies reached it within 43 months; a quarter within 23 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2026
First posted
Apr 14, 2026
StartActual
Feb 16, 2026
Primary completionEst.
Jun 30, 2028
CompletionEst.
Sep 30, 2028
Last update
Apr 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07529275
Lead sponsor
iVascular S.L.U.
Responsible party
Sponsor
First posted
Apr 14, 2026
Start date
Feb 16, 2026
Primary completion
Jun 30, 2028 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Apr 14, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion